What is the 13F Pro Quality Score for RNAZ?

13F Pro ranks Transcode Therapeutics, Inc. (RNAZ) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RNAZ's current score at https://13fpro.ai/research/RNAZ (free sign-up required for the full ranking).

Where does 13F Pro source RNAZ data?

All Transcode Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Transcode Therapeutics, Inc. files with the SEC under CIK 1829635. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RNAZ in?

Transcode Therapeutics, Inc. (RNAZ) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RNAZ research updated on 13F Pro?

RNAZ's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Transcode Therapeutics, Inc.(RNAZ)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1829635 RNAZ stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RNAZ Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Transcode Therapeutics, Inc. (RNAZ), a Healthcare sector company. RNAZ is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Transcode Therapeutics, Inc. reports net income of $-17.8M, free cash flow of $-5.0M. Top institutional holders of RNAZ by reported 13-F value include GEODE CAPITAL MANAGEMENT,, UBS Group AG, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. RNAZ trades on the Nasdaq exchange and files with the SEC under CIK 1829635. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNAZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Transcode Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-17.8M

Free Cash Flow

Q1 2026

$-5.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-97.3% YoY

$-34.7MFY 2025

FY20 $-2.3MFY21 $-6.8MFY22 $-17.6MFY25 $-34.7M

Operating Income

-50.2% YoY

$-28.0MFY 2025

FY20 $-726.6KFY21 $-6.2MFY22 $-18.6MFY25 $-28.0M

EPS (Diluted)

-10.1% YoY

$-52.59FY 2025

FY20 $-0.51FY21 $-0.81FY22 $-47.75FY25 $-52.59

Total Assets

+2040.2% YoY

$162.4MFY 2025

FY20 $1.1MFY21 $22.9MFY22 $7.6MFY25 $162.4M

Op. Cash Flow

-23.8% YoY

$-19.5MFY 2025

FY20 $-493.0KFY21 $-5.3MFY22 $-15.8MFY25 $-19.5M

Metric	FY 2025	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-34.7M -97.3%	$-17.6M -156.7%	$-6.8M -192.0%	$-2.3M	—
Operating Income	$-28.0M -50.2%	$-18.6M -202.9%	$-6.2M -746.6%	$-726.6K	—
EPS (Diluted)	$-52.59 -10.1%	$-47.75 -5794.5%	$-0.81 -58.8%	$-0.51	—
Total Assets	$162.4M +2040.2%	$7.6M -66.9%	$22.9M +2073.5%	$1.1M	—
Operating Cash Flow	$-19.5M -23.8%	$-15.8M -199.3%	$-5.3M -968.4%	$-493.0K	—

AI Insight: RNAZ Financial Trends

Transcode is in severe cash-burn crisis with no revenue, losses accelerating to $18M net income in Q1 2026, and equity volatility suggesting imminent capital structure stress.

• Net income losses deepened from $-5M in Q3 2025 to $-18M in Q1 2026, a 260% quarterly deterioration.

• Operating cash outflow remained persistent at $-4M to $-8M per quarter; no positive cash generation observed across 9-quarter span.

• Equity swung from $10M (Q1 2025) to $1M (Q3 2025) to $10M (Q4 2025) to $1M (Q1 2026), indicating accounting volatility and minimal financial cushion.

⚠ No revenue reported across all 9 quarters—clinical-stage company with no near-term commercial milestone visibility.

⚠ Operating margin deteriorated sharply: $-3M (Q1 2025) to $-18M (Q1 2026). Runway exhaustion likely within 1–2 quarters at current burn.

⚠ Equity at $1M in latest quarter leaves minimal dilution buffer; debt data absent, raising refinancing and dilution risk.

AI Insight: RNAZ Ratio Trends

ROA deteriorated sharply to -45.3% in Q1 2026, extending a multi-quarter decline from -33.1% in Q4 2025.

• ROA worsened from -33.1% in Q4 2025 to -45.3% in Q1 2026, signaling accelerating net losses relative to assets.

• TTM ROA stood at -25.7% as of March 2026, reflecting sustained unprofitability over the trailing twelve months.

⚠ Q1 2026 ROA reached -45.3%, the worst quarterly figure in the dataset; monitor whether this marks a trough or continued deterioration.

⚠ No operational or balance-sheet metrics available; profitability and leverage trends cannot be assessed beyond ROA.

Get alerted when RNAZ's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Transcode Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RNAZ

GEODE CAPITAL MANAGEMENT, LLC
$109.7K12,740 sh
UBS Group AG
$71.4K8,295 sh
VANGUARD CAPITAL MANAGEMENT LLC
$56.4K6,545 sh
VANGUARD FIDUCIARY TRUST CO
$25.7K2,982 sh
Tower Research Capital LLC (TRC)
$2.0K228 sh
WELLS FARGO & COMPANY/MN
$474.0055 sh
SBI Securities Co., Ltd.
$103.0012 sh
ROYAL BANK OF CANADA
$0.008 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$109.7K	12,740
UBS Group AG	$71.4K	8,295
VANGUARD CAPITAL MANAGEMENT LLC	$56.4K	6,545
VANGUARD FIDUCIARY TRUST CO	$25.7K	2,982
Tower Research Capital LLC (TRC)	$2.0K	228
WELLS FARGO & COMPANY/MN	$474.00	55
SBI Securities Co., Ltd.	$103.00	12
ROYAL BANK OF CANADA	$0.00	8

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RNAZ on your watchlist

Track score changes the day Transcode Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RNAZ a good stock to buy?

13F Pro's AI-powered analysis of Transcode Therapeutics, Inc. (RNAZ) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNAZ are available on the RNAZ stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RNAZ?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNAZ. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Transcode Therapeutics, Inc.'s investment landscape.